Trials / Completed
CompletedNCT01701583
Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study looks at changes in cell proteins in people with chronic hives treated with omalizumab.
Detailed description
The purpose of this study is to evaluate for changes in the proteins produced in white blood cells (basophils) in patients with chronic hives who are treated with and respond to omalizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omalizumab | Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center. |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2016-04-01
- Completion
- 2017-10-01
- First posted
- 2012-10-05
- Last updated
- 2020-12-04
- Results posted
- 2020-12-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01701583. Inclusion in this directory is not an endorsement.